Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Non-Current Liabilities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 4.55% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Sep 2025, up 4.55%, and an annual FY2024 reading of $114606.0, down 66.99% over the prior year.
  • Total Non-Current Liabilities was $6.7 million for Q3 2025 at Abvc Biopharma, roughly flat from $6.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $9.7 million in Q2 2023 and bottomed at $1465.0 in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $3.2 million, with a median of $347193.0 recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities plummeted 99.96% in 2023, then skyrocketed 437789.01% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $32522.0 in 2021, then plummeted by 92.49% to $2441.0 in 2022, then skyrocketed by 14123.39% to $347193.0 in 2023, then plummeted by 66.99% to $114606.0 in 2024, then surged by 5752.22% to $6.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ABVC at $6.7 million in Q3 2025, $6.7 million in Q2 2025, and $6.9 million in Q1 2025.